Paulash Mohsen
Chief Executive Officer chez Vesigen, Inc.
Profil
Paulash Mohsen is currently the Chief Executive Officer at Vesigen, Inc. and also holds a position as Chief Business Officer at Yumanity, Inc. Previously, he worked as Vice President-Strategy at Pfizer Inc. from 1997 to 2011.
He also held positions as Country Manager-Canada Region at Cubist Pharmaceuticals LLC and Vice President-Strategy & Business Operations at Optimer Pharmaceuticals LLC.
In addition, he was the Chief Business Officer at Yumanity Therapeutics, Inc. from 2020 to 2022.
Mohsen received his undergraduate degree from Brown University, his graduate degree from Massachusetts Institute of Technology, and his MBA from Harvard Business School.
Postes actifs de Paulash Mohsen
| Sociétés | Poste | Début |
|---|---|---|
Yumanity, Inc.
 Yumanity, Inc. Pharmaceuticals: MajorHealth Technology Yumanity, Inc. engages in transforming drug discovery for neurodegenerative diseases services. It provides integrated discovery platforms, phenotypic screening (uHTS) platforms, in which different protein misfolding pathologies are modeled in yeast to help discover compounds to correct these pathologies; a human neuronal platform. The company was founded by Anthony N. Coles, Jr. and Susan L. Lindquist in December 2014 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
Vesigen, Inc.
 Vesigen, Inc. BiotechnologyHealth Technology Vesigen, Inc. develops groundbreaking therapeutic products directed to intracellular targets using a scalable and extracellular vesicle delivery technology. The company is headquartered in Cambridge, MA. | Chief Executive Officer | 11/04/2022 |
Anciens postes connus de Paulash Mohsen
| Sociétés | Poste | Fin |
|---|---|---|
| YUMANITY THERAPEUTICS | Corporate Officer/Principal | 08/04/2022 |
| PFIZER, INC. | Corporate Officer/Principal | 01/01/2011 |
Optimer Pharmaceuticals LLC
 Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | Corporate Officer/Principal | - |
| CUBIST PHARMACEUTICALS INC | Corporate Officer/Principal | - |
Formation de Paulash Mohsen
| Brown University | Undergraduate Degree |
| Massachusetts Institute of Technology | Graduate Degree |
| Harvard Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | Health Technology |
Yumanity, Inc.
Yumanity, Inc. Pharmaceuticals: MajorHealth Technology Yumanity, Inc. engages in transforming drug discovery for neurodegenerative diseases services. It provides integrated discovery platforms, phenotypic screening (uHTS) platforms, in which different protein misfolding pathologies are modeled in yeast to help discover compounds to correct these pathologies; a human neuronal platform. The company was founded by Anthony N. Coles, Jr. and Susan L. Lindquist in December 2014 and is headquartered in Boston, MA. | Health Technology |
Vesigen, Inc.
Vesigen, Inc. BiotechnologyHealth Technology Vesigen, Inc. develops groundbreaking therapeutic products directed to intracellular targets using a scalable and extracellular vesicle delivery technology. The company is headquartered in Cambridge, MA. | Health Technology |
Yumanity Therapeutics, Inc.
 Yumanity Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Yumanity Therapeutics, Inc. is a clinical stage biopharmaceuticals company. It is accelerating the revolution in the treatment of neurodegenerative diseases through its transformative scientific foundation and drug discovery platform. Its platform is based on technology, which enables the rapid screening for novel disease targets and disease modifying drugs that can overcome toxicity in disease-causing gene networks, which usually results from an aberrant accumulation of misfolded proteins in the brain. The company was founded by Susan Lindquist and Tony Coles in December 2014 and is headquartered in Boston, MA. | Health Technology |
